Bharat Biotech manufactured COVID-19 vaccine Covaxin on Thursday received a certificate of Good Manufacturing Practice compliance from the Hungarian authorities."Another milestone in our account as COVAXIN® receives GMP certificate from Hungary. This marks the 1st EUDRAGDMP compliance certificate received by Bharat Biotech from European regulatories. #BharatBiotech #COVAXIN #covaxininhungary," tweeted Bharat Biotech.
Let us tell you that the approval was received from the National Institute of Pharmacy and Nutrition Hungary certifying the GMP for the manufacture of Covaxin. With this approval, Bharat Biotech achieved another notable milestone in innovating and manufacturing vaccines at global quality norms and moving forward in the continuing fight against the COVID-19 pandemic, read Bharat Biotech statement. The certificate of GMP is now listed on the EudraGMDP database, which is the database of the European Community of manufacturing authorizations and certificates of the good manufacturing practice.
Bharat Biotech also intends to submit documentation for Emergency Use Authorization (EUA) in several additional countries worldwide."The recognition complements our commitment to driving world-class innovation and being a frontrunner in the research and development of vaccines," read the company's statement. Meanwhile, Bharat Biotech's COVID-19 vaccine Covaxin has shown less reduction in 'neutralizing activity' while comparing with Delta and Delta AY.1 variants in those who are fully immunized with the vaccine according to a study by the Indian Council of Medical Research-National Institute of Virology. This means that people vaccinated with Covaxin will be protected against the current variants Delta, Delta AY.1, and B.1.617.3.
Prashant Kishor resigns as Principal Advisor to Punjab CM Amarinder Singh
New Education Policy Rearrangement To See Andhra’s Schools Rise To 58,000
India's this state to be corona-free soon, only this many new cases found in last 24 hours